Caldera Health Limited
To characterise novel diagnostics that detect prostate cancer, and separate indolent from aggressive forms of these cancers.
To commercialise novel and sensitive prostate cancer diagnostics. Seeks funds to run clinical validation studies of ProscanZ™, a blood test comprising a proprietary panel of six biomarkers, which is expected to be a superior prostate cancer diagnostic than the current PSA test, and GuardianZ™, a urine gene test to identify indolent and aggressive prostate cancers. To develop a high throughput genomic platform for the gene expression biomarkers.